&lt;b&gt;Effects of chromium picolinate supplementation in type 2 diabetic patients

Niladê Rosinski Rocha,Ana Carla Pozzi Oliveira,Marcia Regina Batista,Marcia Aparecida Carrara,Talitha Fernandes Stefanello,Caio Jordão Teixeira

doi:10.4025/actascihealthsci.v36i2.17166

<b>Effects of chromium picolinate supplementation in type 2 diabetic patients

Niladê Rosinski Rocha, Ana Carla Pozzi Oliveira + Show 4 more

Open Access

https://doi.org/10.4025/actascihealthsci.v36i2.17166

Copy DOI

Abstract

The effects of chromium picolinate in Type 2 diabetic patients are investigated. Seventeen Type 2 diabetic patients were randomly divided into two groups. The experimental group received fiber-rich hypocaloric diet and chromium picolinate whereas the control group received fiber-rich hypocaloric diet and placebo. The chromium picolinate was offered twice a day at the dose of 100 μg. Anthropometric data such as blood pressure, fasting glycemia and glycated hemoglobin (HbA1c) were measured and these parameters were evaluated again after 90 days. No difference was reported in rates of body weight, waist, hip, body mass index, blood pressure and fasting glycemia (Control vs. Experimental groups) after treatment. However, a decrease (p = 0.0405) of HbA1c occurred in the experimental group when the pre- and post-treatment rates were compared. HbA1c data showed that chromium picolinate improved the glycemic control in Type 2 diabetes.

Highlights

Diabetes is a chronic metabolic disturbance characterized by hyperglycemia due to insulin deficiency and/or resistance
Since chromium administration may be included within the therapeutic design for glycemia control (BROADHURST, DOMENICO, 2006; GEOHAS et al, 2007; KESZTHELYI et al, 2003; KLEEFSTRA et al, 2007; MITA et al, 2005; MUÑOZ et al, 2006; SINGER; GEOHAS, 2006), current research investigates the effects of chromium picolinate supplementation in Type 2 diabetic patients
Nine patients were assigned to the Experimental group that received capsules of chromium picolinate and 8 patients to the Control group that received capsules of placebo, i.e., kaolin, a neutral excipient used in some supplements and medications, which does not affect the patient’s metabolism

Summary

Introduction

Diabetes is a chronic metabolic disturbance characterized by hyperglycemia due to insulin deficiency and/or resistance. Several studies suggest that the supplementation with chromium picolinate may decrease insulin resistance and improve glycemic control in Type 2 diabetic patients, while contributing towards the reduction of hypercholesterolemia and hypertriglyceridemia (FEINER et al, 2008; GOMES et al, 2005). Since chromium administration may be included within the therapeutic design for glycemia control (BROADHURST, DOMENICO, 2006; GEOHAS et al, 2007; KESZTHELYI et al, 2003; KLEEFSTRA et al, 2007; MITA et al, 2005; MUÑOZ et al, 2006; SINGER; GEOHAS, 2006), current research investigates the effects of chromium picolinate supplementation in Type 2 diabetic patients.

Results

Conclusion